| Company Name: |
NCE Biomedical Co.,Ltd. |
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Email: |
|
- TAK-715
-
- $34.00
-
2026-09-10
- CAS:303162-79-0
- Purity: 99.83%
- Supply Ability: 10g
- Tak-715
-
- $9.80
-
2020-01-13
- CAS:303162-79-0
- Min. Order: 1g
- Purity: ≥99%
- Supply Ability: 100kg
|
| | Tak-715 Basic information |
| Product Name: | Tak-715 | | Synonyms: | Tak-715;N-(4-(2-Ethyl-4-(3-methylphenyl)-thiazol-5-yl)pyridin-2-yl)benzamide;BenzaMide, N-[4-[2-ethyl-4-(3-Methylphenyl)-5-thiazolyl]-2-pyridinyl]-;N-(4-(2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl)-2-pyridyl)benzamide;N-(4-(2-Ethyl-4-(m-tolyl)thiazol-5-yl)pyridin-2-yl)benzamide;N-[4-[2-Ethyl-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]benzamide;TAK-715; TAK715;CS-1566 | | CAS: | 303162-79-0 | | MF: | C24H21N3OS | | MW: | 399.51 | | EINECS: | | | Product Categories: | Inhibitors;MAPK | | Mol File: | 303162-79-0.mol |  |
| | Tak-715 Chemical Properties |
| storage temp. | Sealed in dry,2-8°C | | solubility | DMSO: >15mg/mL | | form | powder | | color | faint yellow to dark yellow | | InChI | InChI=1S/C24H21N3OS/c1-3-21-27-22(18-11-7-8-16(2)14-18)23(29-21)19-12-13-25-20(15-19)26-24(28)17-9-5-4-6-10-17/h4-15H,3H2,1-2H3,(H,25,26,28) | | InChIKey | HEKAIDKUDLCBRU-UHFFFAOYSA-N | | SMILES | C(NC1=NC=CC(C2SC(CC)=NC=2C2=CC=CC(C)=C2)=C1)(=O)C1=CC=CC=C1 |
| Hazard Codes | Xn | | Risk Statements | 22-36 | | Safety Statements | 26 | | WGK Germany | 3 | | HS Code | 2934999090 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral
Eye Irrit. 2 |
| | Tak-715 Usage And Synthesis |
| Uses | TAK 715 is a p38 MAPK inhibitor for p38α and p38β but not for p38γ and p38δ. | | Definition | ChEBI: N-[4-[2-ethyl-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]benzamide is a member of benzamides. | | Biological Activity | tak-715 is a selective inhibitor of p38 mapk with ic50 value of 7.1 nm [1].p38 mitogen-activated protein (map) kinases (p38 mapks) are a class of mitogen-activated protein kinases and play an important role in controlling cellular responses to cytokines and stress. four p38 mapks contain members, p38-α (mapk14), p38-β (mapk11), p38-γ (mapk12/erk6), and p38-δ (mapk13/sapk4), have been identified. abnormal expression of p38 mapks are correlated with a variety of chronic inflammatory diseases and their inhibitors are regarded as promising targets in clinical [1] [2].tak-715 is a potent p38 mapk inhibitor and has a different selectivity with the reported p38 mapk inhibitor vx-745. when tested with human monocytic thp-1 cells, administration of tak-715 exhibited inhibition on p38mapkα with ic50 value of 7.1 nm [1]. in hek293t, u2os, and f9 cells, tak-715 was used to inhibit p38 mapk activity and concluded that p38 mapk had no function in wnt/β-catenin signaling pathway [2].in adjuvant-induced rheumatoid arthritis rat model, administration of tak-715 at dose of 10 mg/kg significantly decreased lps-induced stimulated release of tnf-α (87.6%) by inhibiting p38 mapk activity [1]. | | in vivo | TAK-715 (compound 8h; 3-30 mg/kg; PO) significantly reduces the secondary paw volume[1].
TAK-715 (10 mg/kg; PO) has a Cmax of 0.19 μg/mL and an AUC of 1.16 μg h/mL. | Animal Model: | 7-week-old male Lewis rats with arthritis[1] | | Dosage: | 3, 10, 30 mg/kg | | Administration: | PO; single dose | | Result: | Significantly reduced the secondary paw volume (25% inhibition)
|
| Animal Model: | Rat[1] | | Dosage: | 10 mg/kg (Pharmacokinetic Analysis) | | Administration: | PO | | Result: | Had a Cmax of 0.19 μg/mL and an AUC of 1.16 μgh/mL.
|
| | IC 50 | p38α: 7.1 nM (IC50); p38β: 200 nM (IC50); p38δ: >10 μM (IC50); p38γ: >10 μM (IC50); CK1δ; CK1ε | | storage | +4°C | | references | [1]. miwatashi, s., et al., novel inhibitor of p38 map kinase as an anti-tnf-alpha drug: discovery of n-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (tak-715) as a potent and orally active anti-rheumatoid arthritis agent. j med chem, 2005. 48(19): p. 5966-79.
[2]. verkaar, f., et al., inhibition of wnt/beta-catenin signaling by p38 map kinase inhibitors is explained by cross-reactivity with casein kinase idelta/varepsilon. chem biol, 2011. 18(4): p. 485-94. |
| | Tak-715 Preparation Products And Raw materials |
|